Replies to post #221639 on Biotech Values

[DewDiligence]

BMY—My hunch based on the growth of yervoy (after some decline) is that combination therapy in melanoma - which is not SOC - is gaining traction simply based on more comfort with the opdivo and yervoy launch in RCC (especially given the much lower dosing used in renal)...

BMY agrees with you!